Nancy Vander Velde
Overview
Explore the profile of Nancy Vander Velde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verghese C, Brahmbhatt N, Ghous G, Meleveedu K, Vander Velde N, Hunter M, et al.
J Hematol
. 2024 Dec;
13(6):285-289.
PMID: 39697686
Immune checkpoint inhibitors (CPIs) can cause immune-related organ dysfunctions, including nephritis, pneumonitis, thyroiditis, hepatitis, colitis and more rarely hematological toxicities like immune-related autoimmune hemolytic anemia (irAIHA). Very few cases of...
2.
Thuresson P, Vander Velde N, Gupta P, Talbot J
Adv Ther
. 2020 Oct;
37(12):4877-4893.
PMID: 33001384
Introduction: Novel treatment options are needed to improve outcomes in transplant-ineligible relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). This systematic literature review evaluated clinical evidence on treatments for patients...
3.
Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu E, Lin S, et al.
Eur Urol Oncol
. 2019 Apr;
2(1):12-20.
PMID: 30929841
Background: First-line treatments for cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such as atezolizumab (anti-PD-L1). Objective: To compare overall survival (OS) among patients with...
4.
Marshall C, Petersen N, Naik A, Vander Velde N, Artinyan A, Albo D, et al.
Telemed J E Health
. 2014 May;
20(8):705-11.
PMID: 24845366
Background: Tumor board (TB) conferences facilitate multidisciplinary cancer care and are associated with overall improved outcomes. Because of shortages of the oncology workforce and limited access to TB conferences, multidisciplinary...
5.
Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu E, et al.
J Oncol Pract
. 2013 Aug;
9(5):e212-9.
PMID: 23943889
Purpose: This study investigated the treatment patterns and outcomes for US veteran patients with chronic myeloid leukemia-chronic phase (CML-CP) initiated on imatinib (IM). Patients And Methods: Patients (age≥18 years) with...